Besifloxacin: a new fluoroquinolone drug for the treatment of conjunctivitis
XI Yan-bin
ZHANG Yu
YANG Li-qin
KOU Tong-xin
Abstract：Objective:Besifloxacin is a topical ophthalmic agent with broad antibacterial spectrum for the treatment of bacterial conjunctivitis. Besifloxacin is generally equivalent to or better than other fluoroquinolones in activity against most gram-positive and gram-negative pathogens, and anaerobes. Besifloxacin is active against drug-resistant bacteria to fluoroquinolones. Besifloxacin also inhibits pro-inflammatory cytokines in human with bacterial conjunctivitis. In pharmacokinetic studies, besifloxacin can rapidly penetrate into ocular tissues and is sustained in a long time after a single topical dose of besifloxacin ophthalmic suspension. Recent progress in bioactivity, pharmacokinetics, and study of hesifloxacin was briefly reviewed in this paper.
Keywords：besifloxacinpharmacologic actionbacterial conjunctivitispharmacokineticsclinical study
Publication Date：2010-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：3( 267-269 )